Revance Therapeutics

Revance is more than a biotechnology company with a novel drug-delivery platform. We are the integrated sum of our many strengths.

Deep knowledge of drug development, scientific acumen, and prior commercialization experience will enable our team of experts to bring to market a focused portfolio of products that achieve multiple strategic objectives.

We like to dream and think big. Our organization owns aspirations of becoming a global leader in both aesthetic medicine and underserved therapeutic specialties such as as dermatology, neurology, urology, and ophthalmology.

Currently, Revance is advancing two investigational product candidates. Each has the potential to expand practitioner and patient utilization, with the opportunity to capture, retain and grow significant market share.

While our first indications will be used in aesthetic medicine to treat facial wrinkles, we plan to follow with improved therapeutic options that deliver enhanced results, irrespective of use area. Our ultimate mission is to improve the overall patient experience. We know it can be done and we aim to prove it.

Company Growth (employees)
Newark, US
Size (employees)
106 (est)+3%
Revance Therapeutics is headquartered in Newark, US

Revance Therapeutics Office Locations

Revance Therapeutics has an office in Newark
Newark, US (HQ)
7555 Gateway Blvd

Revance Therapeutics Metrics

Revance Therapeutics Financial Metrics

Revance Therapeutics's revenue was reported to be $300 k in FY, 2016

Revenue (FY, 2016)

$300 k

Net income (FY, 2016)

($89.3 m)

EBIT (FY, 2016)

($88.2 m)

Market capitalization (22-May-2017)

$616.1 m

Closing share price (22-May-2017)


Cash (31-Dec-2016)

$63.5 m
Revance Therapeutics's current market capitalization is $616.1 m.
FY, 2014FY, 2015FY, 2016


$383 k$300 k$300 k

Revenue growth, %


R&D expense

$47.5 m$50.4 m

General and administrative expense

$25.1 m$29.1 m

Operating expense total

$72.6 m$88.5 m


($72.3 m)($88.2 m)

EBIT margin, %


Interest expense

($1.2 m)($1.1 m)

Interest income

$231 k$1.2 m

Net Income

($62.9 m)($73.5 m)($89.3 m)
FY, 2014FY, 2015FY, 2016


$171 m$201.6 m$63.5 m

Accounts Receivable

$155.5 m


$1.6 m$1.6 m$7.2 m

Current Assets

$172.7 m$254 m$192.7 m


$19.3 m$19.7 m$10.6 m

Total Assets

$192.5 m$275.8 m$204.4 m

Accounts Payable

$3.1 m$2.7 m$3.8 m

Current Liabilities

$10.2 m$12 m$19.6 m

Additional Paid-in Capital

$435.1 m$585.5 m$598.6 m

Retained Earnings

($258.8 m)$332.3 m($421.5 m)

Total Equity

$253.3 m$177.1 m

Financial Leverage

1.1 x1.2 x
FY, 2014FY, 2015FY, 2016

Net Income

($62.9 m)($73.5 m)($89.3 m)

Depreciation and Amortization

$2.1 m$2 m$1.4 m


($999 k)($192 k)($5.6 m)

Accounts Payable

($3.4 m)($692 k)$953 k

Cash From Operating Activities

($55.1 m)($55.7 m)($59.8 m)

Purchases of PP&E

($7 m)($3.3 m)($1.7 m)

Cash From Investing Activities

($6.9 m)($56.3 m)($75.5 m)

Cash From Financing Activities

$229.1 m$142.6 m($2.6 m)

Interest Paid

$1.2 m$802 k$676 k
Y, 2016


$2.9 k

Financial Leverage

1.2 x

Revance Therapeutics Market Value History

Revance Therapeutics Company Life

You may also be interested in